AUTL – autolus therapeutics plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Autolus Therapeutics (NASDAQ:AUTL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors [Yahoo! Finance]
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: MAK Capital Fund LP
Form 424B3 Autolus Therapeutics
Form 8-K Autolus Therapeutics For: Dec 01
Form S-8 Autolus Therapeutics
Form SCHEDULE 13G Autolus Therapeutics Filed by: ARMISTICE CAPITAL, LLC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.